The opening of the center was successfully conducted to participate in a clinical trial of a biological therapy drug for the treatment of patients with moderate to severe chronic plaque psoriasis, sponsored by Binnopharm Group LLC.
The Ministry of Health approved the center's participation in a clinical trial to study the efficacy and safety of therapy with a drug containing metronidazole and chlorhexidine – Metronidazole + Chlorhexidine, dental gel (Atoll LLC, Russia) compared with Metrogil Denta®, dental gel (JETNL LLC, Russia) and placebo (Ozon LLC, Russia).
The high professional level of our center was confirmed during the audit of the sponsor of one of the clinical trials conducted at our research center. We thank the auditors for their comments and suggestions, which we will definitely take into account in our future work.
Patients with Still's disease will continue to participate in a phase III clinical trial to evaluate the safety and immunogenicity of GNR-086, taken by patients who have completed participation in the CAN-AOSD-III clinical trial, sponsored by GENERIUM JSC, Russia
